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Abstract
Background: The expression of Keratin 19 (K19) was reported in a subset of hepatocellular carcinomas (HCCs). K19
positive HCCs are associated with an increased malignancy compared to K19 negative HCCs. No suitable mouse
models exist for this subtype of HCC, nor is the incidence of K19 expression in hepatocellular neoplasia in model
animals known. Therefore, we compared the occurrence and tumour behaviour of K19 positive hepatocellular
neoplasias in dog and man.
Results: The expression of hepatocellular differentiation (HepPar-1), biliary/progenitor cell (K7, K19), and malignancy
(glypican-3) markers was semi-quantitatively assessed by immunohistochemistry. The histological grade of tumour
differentiation was determined according to a modified classification of Edmondson and Steiner; the staging
included intrahepatic, lymph node or distant metastases. Four of the 34 canine hepatocellular neoplasias showed
K19 positivity (12%), of which two co-expressed K7. K19 positive tumours did not express HepPar-1, despite the
histological evidence of a hepatocellular origin. Like in human HCC, all K19 positive hepatocellular neoplasias were
glypican-3 positive and histologically poorly differentiated and revealed intra- or extrahepatic metastases whereas
K19 negative hepatocellular neoplasias did not.
Conclusions: K19 positive hepatocellular neoplasias are highly comparable to man and occur in 12% of canine
hepatocellular tumours and are associated with a poorly differentiated histology and aggressive tumour behaviour.
Background
Hepatic progenitor cells (HPCs) are activated in the
majority of liver diseases and are a potential cell of ori-
gin for hepatocellular carcinoma (HCC) [1,2]. HCC is a
neoplasm of increasing incidence worldwide and is the
fifth leading cause of death on a worldwide basis in man
[3,4]. Although remarkable advances in surgical and
imaging modalities have improved the prognosis of
HCC patients [5], the high incidence of intrahepatic
recurrence remains a major challenge in HCC therapy
[6,7]. In man the only potentially curative modality for
HCC is surgical resection (including whole organ trans-
plantation), yet recurrence rates are high and the long-
term survival is poor [8]. An additional dilemma is the
limited availability of healthy donor livers. Thus, the
ability to predict individual recurrence risk and subse-
quently prognosis would help guide surgical and che-
motherapeutic treatment. As the understanding of
hepatocarcinogenesis increases, the innumerable genetic
and molecular events that drive the hepatocarcinogenic
disease process, including angiogenesis, invasion and
metastasis, are being unravelled in the human clinical
situation.
Keratin (K) 19 expression is normally found in hepatic
progenitor cells (HPCs) and cholangiocytes but not
hepatocytes [9-11]. However, several authors report the
peculiar expression of K19 in HCC in man [12-15].
These K19 expressing HCCs had a higher rate of recur-
rence (hazard ratio 12.5) after transplantation [6]. Other
studies also linked increased K19 expressions in HCC
with a worse prognosis and faster recurrence after surgi-
cal treatment [14,16-18]. Others observed a significantly
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without any treatment [15]. Furthermore, one recent
report showed that HCCs expressing K19 and K7 have a
l o w e rt u m o u rf r e es u r v i v a lr a t ea f t e rc u r a t i v er e s e c t i o n
[13]. Several studies show that a cut-off of five percent
K19 positive cells already influences the outcome of the
patient [12]. These studies in man validate K19 as a
clinically meaningful and prognostically relevant marker
for hepatocellular carcinoma.
Other recently described markers include glypican-3
(GPC3) which is an extracellular proteoglycan that is
inferred to play an important role in growth control in
embryonic mesodermal tissues in which it is selectively
expressed [19]. GPC3 is a member of the glypican
family of glucosyl-phosphatidylinositol-anchored cell-
surface heparin sulfate proteoglycans and is well estab-
lished as a serologic and immunohistochemical diag-
nostic tool for hepatocellular carcinomas in man. The
presence of GPC3 (mRNA and immuno-histochemis-
try) is much higher in hepatocellular carcinomas com-
pared to cirrhotic tissue or small focal lesions,
indicating that the transition from small premalignant
lesions to hepatocellular carcinomas is associated with
a sharp increase of GPC3 expression in the majority of
cases [20,21].
In view of the similarities in cell biological mechan-
isms involved in regeneration and tumour develop-
ment between human liver tumours and liver tumours
in small domestic animals, it is conceivable that these
acquisitions found in human hepatic tumour pathology
m a ya l s ob et r u ef o rt h ec a n i n el i v e rt u m o u r s[ 2 2 ] .T o
this date, no mouse models exist which resemble K19
positive HCCs in man. Therefore clinicopathological
prognostic markers including marker expression of K7,
K19 (HPC and cholangiocytes), HepPar-1 (hepato-
cytes) and glypican-3 (malignant HCC) were examined
in primary liver tumours of dogs and compared to
man. Results indicate a high similarity in histopathol-
ogy of primary liver tumours between man and dog,
emphasizing the use of dogs as possible treatment
models.
Results
Histological classification of canine primary liver tumours
Liver material of 46 dogs was included in this study
(male to female ratio: 0.7). Breeds represented included
mixed breed, Flat coated retriever, Airedale terrier, Ger-
man Sheppard, Alaskan malamute, Pit bull, Maltezer,
Cocker spaniel, Appenzeller, Golden retriever and
Yorkshire terrier. The age range was six to fourteen
years. Microscopical examination (Table 1) classified the
46 primary liver tumours as: four nodular hyperplasia
(9%) and 34 hepatocellular tumours (74%). Five hepatic
carcinoids (11%) positive for one or more neuro-
endocrine differentiation markers (chromogranin-A,
neuron-specific enolase, and synaptophysin) and three
cholangiocellular carcinomas (7%) were not further ana-
lysed in this study. Apart from the neoplastic changes,
no additional liver pathology was seen in any of the
dogs. Healthy liver tissue was added as a control. Hepa-
tocellular tumours were classified in different groups
based on K19 positivity. Hepatocellular groups were
subdivided in K19 negative and K19 positive. In retro-
spect, all groups were compared with the results of
histological markers (staging and grading) and the
immunohistochemical markers K7, glypican-3, and
HepPar-1.
Nodular hyperplasia (n = 4)
No K19 expression was observed in the nodular hyper-
plasia group (Figure 1A). Histologically, lesions consisted
of double-layered cords of well-differentiated hepato-
cytes and slight compression of the surrounding par-
enchyma. Cells had a similar shape and size, indicating
a good uniformity with no cell pleomorphism. No multi-
nucleated hepatocytes were present. There was no mito-
tic activity and portal areas were present (Figure 1B). All
nodular hyperplasias were negative for Glypican-3 (Fig-
ure 1C) and strongly positive for HepPar-1 (Figure 1D).
Hepatocellular tumour K19 negative (n = 30)
K19 expression in none or less than five percent of the
tumour cells was observed in 30 of the 34 hepatocellular
Table 1 Overview of the canine histological classification.
Groups K19 expression Grading
0t o3
Staging
0t o2
K7 expression Glypican-3 expression HepPar-1 expression
Normal liver
(n = 5)
0% 0 0 0% 0% 100%
Nodular hyperplasia (n = 4) 0% 0 0 0% 0% 100%
Hepatocellular tumour K19 negative
(n = 30)
0-5% 1 (n = 24)
2( n=6 )
0 0% (n = 29)
5% (n = 1)
0% 50-75% (n = 2)
90-100% (n = 28)
Hepatocellular tumour K19 positive (n = 4) 10-90% 3 1 - 2 0% (n = 2)
5% (n = 2)
30-100% 0%
Grouping based on histology and K19 expression in hepatocytes compared with the results of the grading, staging, and clinicopathological markers
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tumours formed trabeculae of well differentiated hepato-
cytes. Cells were uniform in shape and size and with
none to little pleomorphism. The nuclei were round and
regular with minimal nuclear irregularity; the nucleoli
were uniform and sometimes prominent. There were no
multinucleated cells and mitotic figures were absent or
very rare (Figure 2B). In two cases the tumour cells
were not of the same size and were therefore classified
as stage two. However the majority of cells were well
differentiated and occasionally multinucleated cells
could be seen. All tumours were negative for glypican-3
(Figure 2C) and strongly positive for HepPar-1 (Figure
2D).
Hepatocellular tumour K19 positive (n = 4)
Keratin 19 expression in 30-90% of the tumour cells was
seen in four of the 34 hepatocellular tumours (12%)
(Figure 3A). Histologically, these tumours formed
irregular trabeculae and were poorly differentiated
regarding the cell- and nuclear-morphology. The cells
had different shapes and varied in size (anisocytosis).
There was much cell pleomorphism and the cell unifor-
mity disappeared. The nuclei were irregular in shape
and size (anisokaryosis) and some multinucleated cells
could be observed. The nucleoli were very prominent in
shape and colour. The mitotic activity was very high
(Figure 3B). Tumours were categorized in the most
malignant group of the grading system (grade 3) and
classified in stage one or two (due to presence of intra-
hepatic or distant metastasis). The marker glypican-3
was strongly positive (30-100%) for all tumours (Figure
3C) and no HepPar-1 staining was found (Figure 3D).
K19 positive and negative human hepatocellular tumours
(n = 4/group)
Eight human hepatocellular neoplasms were selected of
which four were K19 negative (Figure 4) and four were
Figure 1 Examples of canine nodular hyperplasia. Immunohistochemical staining of K19 negative cells is shown in (A). HE staining, double
layered cords of well differentiated hepatocytes are shown in (B). Absence of immunohistochemical staining for glypican-3 is shown in (C).
Positive immunohistochemical staining for HepPar-1 is shown in (D).
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Page 3 of 11K19 positive in 30 to 90 percent of the tumour cells
(Figure 5). Histologically, the selected K19 negative
tumours were well differentiated and formed trabeculae.
Little pleiomorphism was observed and cells were uni-
form in shape and size. Minimal nuclear irregularity was
seen. Occasionally multinucleated cells were seen and
mitotic figures were absent or rare (Figure 4B). Keratin
negative HCCs were categorized as grade one and classi-
fied in stage 0 due to the lack of vascular invasion in
these samples or distant metastasis (Table 2). All
tumours were negative for glypican-3 (Figure 4C) and
strongly positive for HepPar-1 (Figure 4D). Keratin 19
positive tumours histologically had irregular growth pat-
terns and were poorly differentiated. Tumour cells and
nuclei were polymorph. The mitotic activity was high
(Figure 5B). Tumours were categorized in the most
malignant group of the grading system (grade 3) and
classified in stage one or two (due to presence of
intrahepatic or distant metastasis). The marker glypican-
3 was strongly positive (30-100%) for all tumours (Fig-
ure 5C) and no HepPar-1 staining was found (Figure
5D).
Statistical analysis
Keratin 19 positivity was not found to be linked with
age (P = 0.17). Keratin 19 positivity was negatively cor-
related with HepPar-1 staining (P = 0.001), and posi-
tively correlated with glypican-3 staining (P = 0.0001).
Keratin 19 positive tumours had significantly more dis-
tant metastasis (stage 2) and showed a poorly differen-
tiated histology (grade 3) in comparison with K19
negative tumours (P = 0.001 and 0.0002 respectively).
Discussion
T h ep r e s e n c eo fK 1 9i sas t r ong and independent pre-
dictor of tumour recurrence in man [7,13,14,23,24]. This
Figure 2 Examples of canine K19 negative hepatocellular tumours. Immunohistochemical staining of K19 with a negative tumour field (left)
and positive reactive ductular proliferation at the periphery of the tumour (arrow) is shown in (A). HE staining, trabeculae of well-differentiated
hepatocytes with a uniform appearance are shown in (B). Absence of immunohistochemical staining for Glypican-3 is shown in (C). Positive
immunohistochemical staining for HepPar-1 is shown in (D).
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positive hepatocellular tumours in dogs and clinico-
pathological parameters of these tumours and compared
these with K19 negative and positive hepatocellular
tumours from humans. K19 negative tumours occurred
in 88 percent of the canine hepatocellular tumours.
Tumours with K19 expression was found in twelve per-
cent of the tumours and were correlated with glypican-3
(marker of malignant change) expression and increased
malignancy based on histological grading and staging of
the tumours.
The occurrence of K19 positive hepatocellular carci-
noma in dogs is twelve percent. In man, several studies
estimate the occurrence of the K19 positive phenotype
between 9 and 29 percent (median 17 percent) of all
hepatocellular carcinomas [12,13,15,25,26]. Recently a
study of 417 primary HCCs at the University Hospitals
in Leuven, Belgium, showed that 54 were positive for
K19 (13 percent, data not shown). The high similarity in
occurrence between man and dog confirm the resem-
blance of K19 positive tumours between species.
The presence of progenitor cell features in a tumour
can be explained in two ways: either the cell of origin is
a progenitor cell (maturation arrest theory) or alterna-
tively, tumours dedifferentiate and acquire progenitor
cell features during carcinogenesis (dedifferentiation the-
ory) [23,27]. When progenitor cells are the cells of ori-
gin of a subtype of primary liver tumours, one would
expect that the earliest premalignant precursor lesions
also would consist of progenitor cells and their progeny.
This is indeed the case; 55 percent of small cell dysplas-
tic foci (smaller than 1 mm), the earliest premalignant
lesion known to date in humans, consist of progenitor
cells and intermediate hepatocytes [28]. This is a very
strong argument in favour of the progenitor cell origin
of at least part of the HCCs. Large cell ‘dysplastic’ foci,
Figure 3 Examples of canine hepatocellular tumours with high K19 expression. Immunohistochemical staining of K19 positive cells is
shown in (A). HE staining, trabeculae of hepatocytes with cell pleomorphism and multiple mitotic figures (arrowheads) are shown in (B).
Immunohistochemical staining of glypican-3 positive cells is shown in (C). Immunohistochemical staining for HepPar-1 with tumour negative
area and positive area of surrounding non-neoplastic liver (arrow) is shown in (D).
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cytes being a result of continuous proliferation in
chronic liver diseases and is not the true precursor
lesion of HCC. In the veterinary field, little is known
about markers of HCC or cholangiocarcinoma with only
a few prognostic markers, such as alpha-feto protein
(AFP), investigated [29]. Unfortunately the usefulness of
A F Pa sas e r u mt u m o u rm a r k e ri sq u e s t i o n a b l es i n c e
AFP is only detectable after a significant tumour burden
[30].
In the present study, all the canine hepatocellular
tumours with K19 expression were categorized in the
most malignant group of the grading and staging system
which included presence of infiltrative growth, vascular
invasion and metastases. These features are linked with
a poor prognosis. In contrast, hepatocellular tumours in
dogs which do not express K19 have a benign or less
malignant character because none of these tumours
showed intrahepatic or extrahepatic metastasis and were
classified in group one or two of the grading system.
However, in the progression of the disease it cannot be
excluded that K19 negative tumours will express K19 as
time progresses and thereafter become more malignant
tumours. It is therefore necessary to follow patients with
hepatocellular tumours over time to investigate if these
tumours acquire K19 positivity and show an increase in
malignancy. Serial biopsies are hard if not impossible to
obtain from human livers. In contrast longitudinal stu-
dies are ethically much more accepted in dogs.
I ti su n c l e a rw h e t h e rt h ep r e s e n c eo fK 1 9i sam e d i a -
tor or just an epiphenomenon of a more aggressive phe-
notype. Interestingly, some authors suggest K19
provides tumour cells with a higher metastatic potential
by promoting extracellular matrix degradation and/or
cell mobility [31,32]. In a murine tumour model Chu et
al. established that cells expressing intact keratins had
Figure 4 Examples of K19 negative human hepatocellular tumours. Immunohistochemical staining of K19 negative cells is shown in (A),
positive bile-ducts at the periphery of the tumour indicated by arrow. HE staining, moderately differentiated hepatocytes with trabecular growth
pattern is shown in (B), absence of immunohistochemical staining for Glypican-3 is shown in (C). Positive immunohistochemical staining for
HepPar-1 is shown in (E).
van Sprundel et al. Comparative Hepatology 2010, 9:4
http://www.comparative-hepatology.com/content/9/1/4
Page 6 of 11higher in vitro mobility and invasiveness [33]. In addi-
tion they suggested that intact keratins may act as
anchors for specific cell membrane receptors, conse-
quently reducing cell clustering and aiding cell motility.
It has been shown that the release of keratin-fragments
could contribute to an invasive phenotype [33]. Keratin
fragments are released into the blood by malignant
epithelial cells by activating proteases which degrade
keratins [34-36]. Other authors observed the strong
binding of recombinant K19 to laminin, a major protein
in all basement membranes, provoking an immune
response that damaged the basement membrane [31,32].
These or other mechanisms might contribute to vascular
invasion observed in this study, which remains to be
proven.
In man, glypican-3 (GPC3) can be an important aid in
the morphologically difficult diagnosis between small
HCCs and other small focal lesions. The expression of
GPC3 in a small focal lesion present in a cirrhotic liver
in man is highly indicative of a HCC, irrespective of the
percentage of positive cells. The presence of GPC3
(mRNA and immunohistochemistry) is higher in HCCs
compared to cirrhotic tissue or small focal lesions, indi-
cating that the transition from small premalignant
Figure 5 Examples of K19 positive human hepatocellular tumours. Immunohistochemical staining of K19 positive cells is shown in (A). HE
staining, poorly differentiated HCC with a diffuse growth pattern and multiple mitotic figures (arrowheads) is shown in (B). Immunohistochemical
staining for glypican-3 positive cells is shown in (C). Absence of immunohistochemical staining for HepPar-1 is shown in (D).
Table 2 Overview of the staging and grading of K19 positive hepatocellular tumours in man.
Groups K19 expression Grading
0t o3
Staging
0t o2
K7 expression HepPar-1 expression Glypican-3 expression
Hepatocellular tumour K19 negative (n = 4) 0% 1 0 0 90-100% 0%
Hepatocellular tumour K19 positive (n = 4) 30-90% 3 1 - 2 100% 0% 30-100%
Grouping based on K19 expression compared with the results of the grading, staging, and clinicopathological markers
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GPC3 expression in the majority of cases [21,28].
Because GPC3 is over expressed in human hepatocellu-
lar carcinoma, this marker is used for hepatocellular
tumours in human medicine as a marker for malignant
change [37-39]. In this study, all the canine tumours
with a K19 expression had 30-100% positivity for glypi-
can-3; all the other hepatocellular tumours were nega-
tive for glypican-3. Thus, like K19, expression of
glypican-3 seems to be linked with a poor prognosis.
Therefore, glypican-3 can be used as a marker for hepa-
tocellular malignancy in dogs.
In this study, no K19/GPC3 positive hepatocellular
tumours express the hepatocyte marker HepPar-1. This
is consistent with a HPC phenotype of these tumours as
HPCs/reactive ductules are also negative for HepPar-1.
Another explanation could be that these tumours are
dedifferentiated to the point where they do not express
HepPar-1 anymore. All K19 expressing hepatocellular
tumours which are negative for HepPar-1 are categorized
in the highest (most malignant) groups of the grading
and the staging system. This suggests a negative correla-
tion between the expression of HepPar-1 and prognosis.
Better characterisation of hepatic tumours by cell sur-
face markers and the use of fluorescence activated cell
sorting might in the future contribute to isolation of dif-
ferent tumour cell populations. This will further pave
the way for cell-subset-specific gene expression profiling
of potential tumour stem cells, other tumour cells and
stromal cell populations. In the light of this paradigm,
K19 expression in hepatic tumours might correlate with
the presence of tumour stem cells deriving from hepatic
progenitor cells. If the arising paradigm is verified, a
further deepening of our understanding of hepatocellu-
lar carcinogenesis is expected. Cell-subset-specific gene
expression profiling might indeed uncover specific sig-
nalling pathways in tumour stem cells and interactions
between tumour stem cells, other tumour cells and stro-
mal cells, which might well be masked in gene expres-
sion profiling of the tumour as a whole. Future
prognostic modelling will probably encompass molecular
markers reflecting the biology and natural history of
hepatic tumours [40]. The most interesting perspective
is when these markers will also determine the applicabil-
ity of tailored therapy for which the dog would fit as a
highly relevant model.
Conclusions
K19 positive hepatocellular neoplasias occur in twelve
percent of hepatocellular neoplasias and are associated
with a poorly differentiated histology and more aggres-
sive tumour behaviour. K19 expression correlates with
the expression of glypican-3 and with the disappearance
of the hepatocyte marker HepPar-1 and are valuable
clinicopathological and prognostic markers in the histo-
pathological diagnosis of hepatocellular tumours in
dogs. K19 positive tumours are highly comparable in
histology, marker expression, and prevalence to their
human counterparts thus advocating the dog as a model
for future anti-tumour treatment.
Methods
Samples
For this study paraffin material of a wide variety of pri-
mary liver tumours was available from the paraffin
material archive present at the department of Patho-
biology, Faculty of Veterinary Medicine, Utrecht Uni-
versity (dog, n = 20), Valuepath, Laboratory for
Veterinary Pathology, Hoensbroek, The Netherlands
( d o g ,n=1 9 ) ,a n dU n i v e r s i t yH o s p i t a l sL e u v e n ,L e u -
ven, Belgium (man, n = 8). In addition, frozen material
(dog, n = 7) was available from the tissue bank present
at the Department of Clinical Sciences of Companion
Animals, Faculty of Veterinary Medicine, Utrecht Uni-
versity. All the material was derived from patients who
were submitted for individual diagnostic purposes; no
tissue was taken purposely for the reported study.
Healthy canine liver samples embedded in paraffin
were also available from the Department of Clinical
Sciences of Companion Animals, Faculty of Veterinary
Medicine, Utrecht University derived from non-liver
related research. As a positive control paraffin-
embedded liver tissue samples from dogs with fulmi-
nant hepatitis and reactive ductular proliferation of
HPCs were used (courtesy Dr. J. IJzer, Department of
Pathobiology, Faculty of Veterinary Medicine, Utrecht
University). All liver tumour samples and fulminant
hepatitis samples were fixed in 10% neutral buffered
formalin and routinely embedded in paraffin. The par-
affin sections (4 μm) were mounted on poly-L lysine
coated slides. All the sections (4 μm) were stained with
haematoxylin and eosin (HE) for histological determi-
nation. To exclude hepatic carcinoids in this study, the
following neuro-endocrine differentiation markers were
used; chromogranin-A, neuron-specific enolase, and
synaptophysin, data not shown [41-43].
Grading
Histological grading of malignant tumours is based on
the grading system of Edmondson and Steiner (ES grad-
ing system). The ES grading uses a scale of one to four,
with increasing nuclear irregularity, hyperchromatism
and nuclear/cytoplasmic ratio, associated with decreas-
ing cytological differentiation for each successively
higher grade. The grading system designed for this
study is based on the ES differentiation grade and is
modified into a four category grading system based on
cell morphology (anisocytosis), nuclear morphology
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and mitotic activity.
Staging
Staging describes the extent or severity of a cancer based
on the extent of the original (primary) tumour and the
extent of spread in the body. The TNM system is one of
the most commonly used staging systems. This system
has been accepted by the international union against can-
cer (UICC) and the American Joint Committee on Can-
cer (AJCC). The TNM system is based on the extent of
the tumour (T), the extent of spread to the lymph nodes
(N), and the presence of distant metastasis (M). A num-
ber is added to each letter to indicate the size or extent
of the tumour and the extent of spread. The staging sys-
tem used for this study is based on the spread of the
tumour through the body, and therefore considered sum-
mary staging. Many cancer registries, such as the
National Cancer Institutes (NCI) surveillance use sum-
mary staging. The staging system used for this study is a
modified three category staging system and is based on
t h ei n v a s i o na n ds p r e a do ft h et u m o u r .T h et u m o u r sa r e
staged in three categories: Stage 0: macroscopically there
is only one tumour process in the liver and/or microsco-
pically the tumour is well circumscribed or encapsulated.
There are no indications for intrahepatic or extrahepatic
metastases; Stage 1: Microscopically the tumour has
spread beyond the original (primary) site to the adjacent
tissue and/or vessels or microsatellites can be seen and/
or there are macroscopically multiple tumour processes
present in the liver; Stage 2: The tumour has spread from
the primary site to the lymph node and/or other organs
(distant metastasis).
Immunohistochemistry
Immunohistochemistry (IHC) was performed for K19,
K7, HepPar-1, and glypican-3 (GPC-3) on all liver
tumour samples. Antibody characteristics, manufacturer,
source and dilution are provided in Table 1. Slides were
air dried (30 min, RT) and deparaffinised. Heat induced
antigen retrieval was performed with 10 mM citrate buf-
fer (pH 6.0) or 10 mM Tris with 1 mM EDTA for 10
minutes in a microwave (850 W) with a cool down per-
iod for 10 minutes at RT (Table 3). Antigen retrieval by
enzymatic digestion was performed with proteinase K
for 15 minutes at room temperature (Table 3). Endogen-
ous peroxidase activity was blocked in 0.3% H2O2 (30
min) and background staining was blocked with 10%
normal goat serum (30 min). The primary antibodies
were diluted in the appropriate buffer and incubated as
indicated in Table 3. The Envision system was used for
secondary antibody labelling (Dakocytomation, Glostrup,
Denmark). The signal was developed in 0.06% 3,3’-dia-
minobenzidine (DAB) solution (Dakocytomation) for 5
minutes and finally counterstained with Mayer’sh e m a -
toxylin (Mayer’s haematoxylin, Klinipath B.V. Duiven,
The Netherlands). Negative controls were performed by
replacing the primary antibody with washing buffer.
Bile-ducts served as an internal positive control for K7
and K19. Hepatocytes from healthy tissue served as a
positive control for HepPar-1. Human hepatocellular
carcinomas, previously tested to be glypican-3 positive
(Department of Morphology and Molecular Pathology,
University Hospitals Leuven, Leuven, Belgium) served as
a positive control for glypican-3. Staining of human
samples for keratin 19, glypican-3, and HepPar-1 were
performed as described previously [12,28,44].
Statistics
Two-tailed Fisher’s Exact Test was performed to assess
associations between keratin 19 positivity and categori-
cal data such as grading, staging, K7 positivity, HepPar-
1 positivity, and glypican-3 positivity. Unpaired t-test
was performed to assess global association between ker-
atin 19 positivity and normally-distributed continuous
variable of age. A P-value below 0.05 was considered to
be significant.
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